Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: May 2022
Date Filed: May 26, 2022
Principal Executive Office: Level 3, 460 Bourke Street, Melbourne, VIC 3000, Australia
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on corporate events rather than financial performance data.
Material Changes
No material financial changes versus prior periods are disclosed in this filing. The primary update is the announcement of a corporate event.
Guidance, Outlook, and Management Commentary
- Corporate Event: Alterity Therapeutics Limited will participate in the Benchmark Company Conference (Exhibit 99.1).
- Registration Statements: This Form 6-K is incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-251647, 333-249311, 333-231417, 333-250076).
- Risks and Contingencies: No specific risks or contingencies are detailed in this summary text.
Investor Verification Checklist
- Verify the date and agenda of the Benchmark Company Conference participation.
- Review the referenced Form S-8 and Form F-3 registration statements for details on equity offerings.
- Confirm the company's current cash runway and burn rate in the most recent Form 20-F, as this 6-K contains no financial data.